Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Corporate Development | May 01, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,365 |
Ending reported balance
After 2026-05-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-01 · Exercise / conversion · Acquired 939 · Balance 6,820 Row 2 · 2026-05-01 · Tax withholding · Disposed 455 · Balance 6,365 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2026-05-01 | Direct | 0 |
Reported balance
After 2026-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-01 · Exercise / conversion · Disposed 939 · Balance 0 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of May 1, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of May 1, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 5, 2026 20:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 939 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000046 · form4.xml · derivative · entry 3 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 939 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of May 1, 2023. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 455 | $187.06 | $85,112.30 |
DisclosureSEC source: 0000875045-26-000046 · form4.xml · nonDerivative · entry 2 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,365 Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:11 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 939 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000046 · form4.xml · nonDerivative · entry 1 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 01:12 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 8,025 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000031 · form4.xml · derivative · entry 1 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,025 Underlying: Common Stock · 8,025 shares Expires 2029-02-13 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 3,278 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000020 · form4.xml · derivative · entry 6 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,557 Underlying: Common Stock · 3,278 shares Expires 2028-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,802 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000020 · form4.xml · derivative · entry 5 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,802 Underlying: Common Stock · 1,802 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 994 | $201.18 | $199,972.92 |
DisclosureSEC source: 0000875045-26-000020 · form4.xml · nonDerivative · entry 4 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,881 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 3,278 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000020 · form4.xml · nonDerivative · entry 3 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 589 | $201.18 | $118,495.02 |
DisclosureSEC source: 0000875045-26-000020 · form4.xml · nonDerivative · entry 2 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,597 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,802 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000020 · form4.xml · nonDerivative · entry 1 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:19 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 938 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013346 · form4.xml · derivative · entry 3 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 939 Underlying: Common Stock · 938 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of May 1, 2023. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:19 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 454 | $120.93 | $54,902.22 |
DisclosureSEC source: 0001127602-25-013346 · form4.xml · nonDerivative · entry 2 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,384 Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:19 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 938 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013346 · form4.xml · nonDerivative · entry 1 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:51 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,801 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003960 · form4.xml · derivative · entry 4 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,604 Underlying: Common Stock · 1,801 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:51 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 563 | $141.35 | $79,580.05 |
DisclosureSEC source: 0001127602-25-003960 · form4.xml · nonDerivative · entry 2 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,900 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:51 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003960 · form4.xml · nonDerivative · entry 1 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 23:51 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 9,835 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003960 · form4.xml · derivative · entry 3 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,835 Underlying: Common Stock · 9,835 shares Expires 2028-02-06 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| May 01, 2024 Filed May 4, 2024 00:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 938 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014199 · form4.xml · derivative · entry 3 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,877 Underlying: Common Stock · 938 shares Expires 2026-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of May 1, 2023. Read SEC document |
| May 01, 2024 Filed May 4, 2024 00:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 276 | $216.13 | $59,651.88 |
DisclosureSEC source: 0001127602-24-014199 · form4.xml · nonDerivative · entry 2 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 662 Read SEC document |
| May 01, 2024 Filed May 4, 2024 00:00 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 938 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014199 · form4.xml · nonDerivative · entry 1 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2024 Filed Feb 10, 2024 01:08 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 5,405 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004307 · form4.xml · derivative · entry 1 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,405 Underlying: Common Stock · 5,405 shares Expires 2027-02-07 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| May 01, 2023 Filed May 3, 2023 00:08 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 2,815 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014148 · form4.xml · derivative · entry 2 Keeney Adam · CIK 0001973607 · Head of Corporate Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,815 Underlying: Common Stock · 2,815 shares Expires 2026-05-01 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of May 1, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.